Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control.

Autor:	Gandasegui J; Barcelona Institute for Global Health, Hospital Clínic Universitat de Barcelona, Barcelona, Spain., Onwuchekwa C; Barcelona Institute for Global Health, Hospital Clínic Universitat de Barcelona, Barcelona, Spain., Krolewiecki AJ; Barcelona Institute for Global Health, Hospital Clínic Universitat de Barcelona, Barcelona, Spain; Instituto de Investigaciones de Enfermedades Tropicales, Universidad Nacional de Salta, Orán, Argentina., Doyle SR; Wellcome Sanger Institute, Hinxton, UK., Pullan RL; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK., Enbiale W; Bahir Dar University, College of Medicine and Health Science, Bahir Dar, Ethiopia; Amsterdam UMC, University of Amsterdam, Department of Dermatology, Amsterdam Institute for Infection and Immunity, Academic Medical Centre, Amsterdam, Netherlands., Kepha S; Eastern and Southern Africa Centre of International Parasite Control, Nairobi, Kenya; Medical Research Institute, Nairobi, Kenya., Hatherell HA; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK., van Lieshout L; Department of Parasitology, Leiden University Medical Centre, Leiden, Netherlands., Cambra-Pellejà M; Instituto de Ganadería de Montaña, Consejo Superior de Investigaciones Científicas Universidad de León, Grulleros, Spain; Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de León, Campus de Vegazana, León, Spain., Escola V; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique., Muñoz J; Barcelona Institute for Global Health, Hospital Clínic Universitat de Barcelona, Barcelona, Spain. Electronic address: jose.munoz@isglobal.org.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2022 Nov; Vol. 22 (11), pp. e341-e347. Date of Electronic Publication: 2022 Jul 15.
DOI:	10.1016/S1473-3099(22)00369-3
Abstrakt:	In 2020, WHO recognised the importance of strongyloidiasis alongside soil-transmitted helminths (STH) in their 2021-30 roadmap, which aspires to target Strongyloides stercoralis with preventive chemotherapy by use of ivermectin. Combination treatment with both albendazole, the primary drug used to treat STH, and ivermectin, would improve the efficiency of mass drug administration targeting both STH and S stercoralis. In this Personal View, we discuss the challenges and opportunities towards the development of an efficient control programme for strongyloidiasis, particularly if it is to run concurrently with STH control. We argue the need to define the prevalence threshold to implement preventive chemotherapy for S stercoralis, the target populations and optimal dosing schedules, and discuss the added benefits of a fixed-dose coformulation of ivermectin and albendazole. Implementation of an efficient control programme will require improvements to current diagnostics, and validation of new diagnostics, to target and monitor S stercoralis infections, and consideration of the challenges of multispecies diagnostics for S stercoralis and STH control. Finally, the evolution of ivermectin resistance represents a credible risk to control S stercoralis; we argue that genome-wide approaches, together with improved genome resources, are needed to characterise and prevent the emergence of resistance. Overcoming these challenges will help to reduce strongyloidiasis burden and enhance the feasibility of controlling it worldwide. Competing Interests: Declaration of interests We declare no competing interests. (Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu